Curtin M - Search Results

1

Pharmacology of ABT-491, a highly potent platelet-activating factor receptor antagonist.

Albert DH, Magoc TJ, Tapang P, Luo G, Morgan DW, Curtin M, Sheppard GS, Xu L, Heyman HR, Davidsen SK, Summers JB, Carter GW. Albert DH, et al. Among authors: curtin m. Eur J Pharmacol. 1997 Apr 23;325(1):69-80. doi: 10.1016/s0014-2999(97)00109-x. Eur J Pharmacol. 1997. PMID: 9151941

2

Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.

Glaser KB, Li J, Marcotte PA, Magoc TJ, Guo J, Reuter DR, Tapang P, Wei RQ, Pease LJ, Bui MH, Chen Z, Frey RR, Johnson EF, Osterling DJ, Olson AM, Bouska JJ, Luo Y, Curtin ML, Donawho CK, Michaelides MR, Tse C, Davidsen SK, Albert DH. Glaser KB, et al. Among authors: curtin ml. J Pharmacol Exp Ther. 2012 Dec;343(3):617-27. doi: 10.1124/jpet.112.197087. Epub 2012 Aug 30. J Pharmacol Exp Ther. 2012. PMID: 22935731

3

ABT-491, a highly potent and selective PAF antagonist, inhibits nasal vascular permeability associated with experimental allergic rhinitis in brown Norway rats.

Albert DH, Tapang P, Morgan DW, Curtin ML, Sheppard GS, Davidsen SK, Summers JB, Carter GW. Albert DH, et al. Among authors: curtin ml. Inflamm Res. 1997 Aug;46 Suppl 2:S133-4. doi: 10.1007/s000110050141. Inflamm Res. 1997. PMID: 9297547 No abstract available.

4

The role of platelet-activating factor (PAF) and the efficacy of ABT-491, a highly potent and selective PAF antagonist, in experimental allergic rhinitis.

Albert DH, Malo PE, Tapang P, Shaughnessy TK, Morgan DW, Wegner CD, Curtin ML, Sheppard GS, Xu L, Davidsen SK, Summers JB, Carter GW. Albert DH, et al. Among authors: curtin ml. J Pharmacol Exp Ther. 1998 Jan;284(1):83-8. J Pharmacol Exp Ther. 1998. PMID: 9435164

5

Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonists.

Curtin ML, Davidsen SK, Heyman HR, Garland RB, Sheppard GS, Florjancic AS, Xu L, Carrera GM Jr, Steinman DH, Trautmann JA, Albert DH, Magoc TJ, Tapang P, Rhein DA, Conway RG, Luo G, Denissen JF, Marsh KC, Morgan DW, Summers JB. Curtin ML, et al. J Med Chem. 1998 Jan 1;41(1):74-95. doi: 10.1021/jm970389+. J Med Chem. 1998. PMID: 9438024

6

Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.

Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK. Wada CK, et al. J Med Chem. 2002 Jan 3;45(1):219-32. doi: 10.1021/jm0103920. J Med Chem. 2002. PMID: 11754593

7

Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors.

Dai Y, Guo Y, Frey RR, Ji Z, Curtin ML, Ahmed AA, Albert DH, Arnold L, Arries SS, Barlozzari T, Bauch JL, Bouska JJ, Bousquet PF, Cunha GA, Glaser KB, Guo J, Li J, Marcotte PA, Marsh KC, Moskey MD, Pease LJ, Stewart KD, Stoll VS, Tapang P, Wishart N, Davidsen SK, Michaelides MR. Dai Y, et al. J Med Chem. 2005 Sep 22;48(19):6066-83. doi: 10.1021/jm050458h. J Med Chem. 2005. PMID: 16162008

8

Thienopyridine urea inhibitors of KDR kinase.

Heyman HR, Frey RR, Bousquet PF, Cunha GA, Moskey MD, Ahmed AA, Soni NB, Marcotte PA, Pease LJ, Glaser KB, Yates M, Bouska JJ, Albert DH, Black-Schaefer CL, Dandliker PJ, Stewart KD, Rafferty P, Davidsen SK, Michaelides MR, Curtin ML. Heyman HR, et al. Among authors: curtin ml. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1246-9. doi: 10.1016/j.bmcl.2006.12.015. Epub 2006 Dec 9. Bioorg Med Chem Lett. 2007. PMID: 17188869

9

Broad spectrum matrix metalloproteinase inhibitors: an examination of succinamide hydroxamate inhibitors with P1 C alpha gem-disubstitution.

Curtin ML, Garland RB, Davidsen SK, Marcotte PA, Albert DH, Magoc TJ, Hutchins C. Curtin ML, et al. Bioorg Med Chem Lett. 1998 Jun 16;8(12):1443-8. doi: 10.1016/s0960-894x(98)00255-8. Bioorg Med Chem Lett. 1998. PMID: 9873367

10

Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors.

Michaelides MR, Dellaria JF, Gong J, Holms JH, Bouska JJ, Stacey J, Wada CK, Heyman HR, Curtin ML, Guo Y, Goodfellow CL, Elmore IB, Albert DH, Magoc TJ, Marcotte PA, Morgan DW, Davidsen SK. Michaelides MR, et al. Among authors: curtin ml. Bioorg Med Chem Lett. 2001 Jun 18;11(12):1553-6. doi: 10.1016/s0960-894x(01)00031-2. Bioorg Med Chem Lett. 2001. PMID: 11412979

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

208 results

Search Page